A systematic review of biomarkers for disease progression in Parkinson's disease by McGhee, David J M et al.
McGhee et al. BMC Neurology 2013, 13:35
http://www.biomedcentral.com/1471-2377/13/35RESEARCH ARTICLE Open AccessA systematic review of biomarkers for disease
progression in Parkinson’s disease
David JM McGhee1*, Pamela L Royle2, Paul A Thompson3, David E Wright3, John P Zajicek4 and Carl E Counsell1Abstract
Background: Using surrogate biomarkers for disease progression as endpoints in neuroprotective clinical trials may
help differentiate symptomatic effects of potential neuroprotective agents from true disease-modifying effects. A
systematic review was undertaken to determine what biomarkers for disease progression in Parkinson’s disease (PD)
exist.
Methods: MEDLINE and EMBASE (1950–2010) were searched using five search strategies. Abstracts were assessed
to identify papers meriting review in full. Studies of participants with idiopathic PD diagnosed by formal criteria or
clearly described clinical means were included. We made no restriction on age, disease duration, drug treatment, or
study design. We included studies which attempted to draw associations between any tests used to investigate
disease progression and any clinical measures of disease progression. The electronic search was validated by
hand-searching the two journals from which most included articles came.
Results: 183 studies were included: 163 (89%) cross-sectional, 20 (11%) longitudinal. The electronic search strategy
had a sensitivity of 71.4% (95% CI 51.1-86.0) and a specificity of 97.1% (95% CI 96.5-97.7). In longitudinal studies
median follow-up was 2.0 years (IQR 1.1-3.5). Included studies were generally poor quality - cross-sectional with
small numbers of participants, applying excessive inclusion/exclusion criteria, with flawed methodologies and
simplistic statistical analyses.
Conclusion: We found insufficient evidence to recommend the use of any biomarker for disease progression in PD
clinical trials, which may simply reflect the poor quality of research in this area. We therefore present a provisional
‘roadmap’ for conducting future disease progression biomarker studies, and recommend new quality criteria by
which future studies may be judged.
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Parkinson’s disease (PD) is the second most common
progressive neurodegenerative disorder, with an annual
incidence of around 16–19 cases per 100,000 [1]. As
drug therapy in PD is currently symptomatic in nature,
a key aim of PD research is the development of drugs
which slow or even halt neurodegeneration and, there-
fore, clinical progression. However, clinical trials in neu-
rodegenerative disorders have struggled to separate out
symptomatic effects of potential therapeutic agents (e.g.
due to increased striatal dopamine) from true disease-
modifying effects. In PD, it is currently not possible to* Correspondence: david.mcghee@abdn.ac.uk
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reproduction in any medium, provided the ordirectly measure the number of remaining dopaminergic
neurons in vivo and, therefore, alternative approaches are
required. Clinical assessments in PD using scales to meas-
ure motor impairment, disability, quality of life, or disease
stage scales are affected by symptomatic effects of therapy
and are unable to differentiate this effect from disease-
modification, at least in the short-term.
Various clinical trial designs have been developed to try
to adjust for symptomatic effects of putative neuro-
protective agents and, therefore, allow clinical rating scales
to be used as endpoints. These include long-term follow
up studies of placebo-treated and active-agent treated
patients looking for ongoing divergence, measuring out-
comes following a wash-out period [2,3], and delayed start
trial design [4]. However, limitations and flaws in thesel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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approach, the focus of much primary research, is the use
of a surrogate outcome biomarker as an endpoint in
neuroprotective clinical trials.
Surrogate outcome biomarkers are objectively measured
characteristics of a disease, which act as indicators of the
underlying pathogenic process responsible for disease
progression, including the change in that process follow-
ing a therapeutic intervention [5,6]. To allow their use in
clinical trials surrogate outcome biomarkers must have a
strong association with a clinical endpoint or outcome
known to measure the effect of a therapeutic intervention
on disease progression, for which the biomarker can act as
a substitute. Surrogate biomarkers for disease progression
in PD could shorten the duration of phase III trials and
thereby reduce the cost and time required to get a drug to
market. Unfortunately at present there is not a single ac-
cepted surrogate outcome biomarker for any neurodegen-
erative disorder. Table 1 outlines the ideal characteristics
of a surrogate biomarker for disease progression in PD.
Much has been written about what features biomarkers
for disease progression in Parkinson’s disease should po-
ssess [7,8]. The ideal surrogate biomarker should:
(1) Change with neurodegeneration (i.e. degeneration
of the nigrostriatal dopaminergic system);
(2) Show an association with the clinical phenotype
arising secondary to this degenerative process;
(3) Have a direct association with disease
progression, without intermediate variables;
(4) Have robust longitudinal data linking it to disease
progression;
(5) Not be influenced by symptomatic treatment, but only
by a true change in the neurodegenerative process;
(6) Predict long-term changes in disease progression
by short-term changes in the biomarker;Table 1 Study quality questionnaire based on the assay meth
recommendations for prognostic tumour markers [18]
Question Ye
(1) Was the study prospective? The study reports that p
test result were collected
of an outcome.
(2) Was evaluation of prognostic marker
blinded to patient outcome?
The study reports an att
measuring the biomarke
(3) Was there a defined time period during
which patients were enrolled?
Study defines time perio
and median follow-up ti
(4) Were there precisely defined clinical
outcomes at the start of the study?
Study defines which clin
measured.
(5) Were the methods for measuring the
prognostic marker adequately described and
referenced?
Clearly described and re
(6) Cases unselected and unbiased? No attempt to select pa(7) Be generalisable to people with differing
characteristics (e.g. age, gender, race);
(8) Be continually variable (ideally linearly for
simplicity);
(9) Be sensitive, reflecting small changes in disease
progression;
(10) Be quick and cheap to measure, and amenable to
blinded assessment;
(11) Be suitable for measurement reliably across
different centres;
(12) Be suitable for repeated measurement in the
same patient;
(13) Be safe and tolerable to the patient.
PD is a complex neurodegenerative disorder in which
many different pathophysiological processes have been
identified in the nigrostriatal pathways and beyond, such
as protein aggregation, oxidative damage, mitochondrial
dysfunction, lysosomal dysfunction and inflammation. It
is, therefore, not surprising that many different candi-
date biomarkers for disease progression in PD have been
studied. However, the literature in this area has never
been brought together systematically. We, therefore,
aimed to undertake a systematic review to assess what
potential surrogate biomarkers for disease progression
(motor and non-motor) in PD exist, whether any meet
the criteria for use in clinical trials, and if not which
looks most promising. We did not aim to review the lit-
erature for diagnostic biomarkers (i.e. those designed to
aid early diagnosis in the pre-motor or motor phase) or
prognostic biomarkers (i.e. those aimed at identifying
patients who progress at different rates). In addition, we
aimed to critique data from identified disease progres-
sion biomarker studies relating to study design, partici-
pant characteristics, and statistical analyses undertaken,
in order to produce guidelines for future studies.ods and study design sections of the REMARK reporting
s = 1 No = 0
atients and the performed
before the development
No report or clearly retrospective (e.g.
patients with poor prognosis collected
before biomarker measurement).
empt to blind the person
r to patient outcome.
There is no such report, or assessor
clearly not blinded.
d, end of follow-up period,
me.
Does not define criteria.
ical end points are to be No such definition.
ferenced Not clearly described and referenced
tients with exclusion criteria Only a subset of patients enter the study
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Following the development of a review protocol equi-
valent to the methodology described below, literature
searches were conducted in the databases MEDLINE
(1950 to August 2010) and Embase (1980 to August
2010), using the OVID search interface. Five separate
search strategies, developed by an experienced informa-
tion scientist, were run in each database. The first four
were based on free-text words identified through back-
ground reading of relevant review articles. These searches
included potential (1) blood, (2) urine or cerebrospinal fluid
(CSF), (3) imaging and (4) neurophysiological biomarkers.
A fifth search using generic terms for biomarkers based on
index headings was also run in both databases. For details
of the search strategy please see Additional file 1.
The searches were limited to human studies. Only
English language articles were included, due to lack of
resources for translation. Reference lists of included arti-
cles and relevant review articles were checked to identify
any studies which the electronic search may have missed.Validation of the electronic search strategy
The electronic search strategy was validated by hand
searching five years of the two journals from which most
of the included articles came: Movement Disorders
(2002–2006) and Journal of the Neurological Sciences
(1992–1996). The number of relevant and irrelevant arti-
cles identified by hand searching and by the electronic
search, was used to calculate the sensitivity and specifi-
city for the electronic search strategy.Study selection
A single reviewer examined abstracts retrieved by the
electronic search to identify articles meriting review in
full. Full length articles were then reviewed before data
were extracted from relevant papers. In both stages the
inclusion and exclusion criteria detailed below were
applied.
Only studies of participants with idiopathic Parkinson’s
disease diagnosed by formal criteria [9-12], or clearly
described clinical means (the presence of at least two
out of four of the cardinal clinical signs of PD and an
attempt to exclude atypical syndromes), were included.
No restriction was made on the grounds of participant’s
age, disease duration, or drug treatment.
Studies which investigated the efficacy of using a bio-
marker, including (but not restricted to) imaging, blood
tests, tests of CSF and neurophysiological tests, to inves-
tigate disease progression in Parkinson’s disease were
included. To qualify for inclusion there must have been
an attempt to examine for an association between the
biomarker and a clinical measure of disease progression.
Acceptable measures included measures of motor orcognitive impairment, disability, handicap, quality of life,
and duration of survival.
Only studies exploring associations between a bio-
marker and the total score from a clinical rating scale,
rather than its subsections, were included. The subsec-
tions of most clinical measures would never be accept-
able outcome measures for neuroprotective trials and,
therefore, developing surrogate biomarkers for these was
felt not to be relevant. The exception was the Unified
Parkinson’s disease rating scale (UPDRS) [13], where
studies examining for relationships to its main constitu-
ent parts were included. Studies only investigated the
relationship between a biomarker and individual symp-
toms (e.g. bradykinesia or rigidity), or olfactory function
were excluded for similar reasons.
Only studies examining for associations between putative
biomarkers and global measures of cognition (e.g. Mini-
mental state examination (MMSE) [14], Cambridge cogni-
tive examination (CAMCOG [15])), rather than individual
neuropsychological tests, were included. It is unlikely that
improvement in a single neuropsychological test would be
a suitable outcome measure for a neuroprotective trial. As
depression in PD is not linked to overall disease progres-
sion [16] and may be commoner at the time of diagnosis
[17], studies only investigating the relationship between a
biomarker and depression were excluded.
Studies examining the relationship between a biomarker
and treatment status, the presence or severity of complica-
tions related to therapy, or duration of illness were ex-
cluded. Studies of static predictive biomarkers (e.g. genetic
markers) which try to anticipate the future rate of disease
progression were excluded. A useful biomarker for clinical
trials needs to be dynamic - changing with disease pro-
gression. Therefore, these studies were not relevant.
As we aimed to produce a comprehensive review and
detect any evidence of the utility of a putative biomarker,
we set no study quality threshold. We, therefore, included
small cross-sectional studies, in which an association
between a biomarker and clinical measures of disease
progression were analysed at a single time point across
groups of patients with different disease severities.
Data extraction
Study methods and results were extracted by a single re-
viewer, and for accuracy this was performed twice. Data
were extracted using a data extraction sheet (Additional
file 2) relating to the following: (1) study design includ-
ing restrictiveness of criteria for entry into the study;
(2) setting; (3) study population, including number of
participants, gender ratio, disease duration at baseline,
baseline measures of disease severity and baseline treat-
ment status; (4) specific biomarkers investigated; (5) statis-
tical analyses performed; (6) results of statistical analyses
of the associations between the biomarkers and clinical
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sults were reported; (7) analysis of the effect of drug treat-
ment on the biomarker; (8) economic analysis of using the
biomarker; (9) measures of suitability and acceptability of
the test to patients.
The restrictiveness of the inclusion and exclusion cri-
teria applied in each study was graded as: none, explicit
statement that only criteria to exclude atypical parkinso-
nian syndromes were applied; mild, ≤ 3 criteria applied
(except those described under moderate); moderate, 4–5
criteria applied or evidence of an attempt to limit by age,
gender, cognitive state, disease stage, drug therapy for PD
(e.g. all de-novo); severe, ≥ 6 criteria applied; not detailed,
no mention of whether criteria were applied.
Methodological quality
No validated tool to measure the quality of studies in-
vestigating surrogate biomarkers as outcome measures
exists. An attempt was, therefore, made to assess study
quality using an adapted quality questionnaire, illus-
trated in Table 1, based on the assay methods and study
design sections of the Reporting recommendations for
tumor MARKer prognostic studies (REMARK) reporting
recommendations for prognostic tumour markers [18].
This measure of study quality was also used to assess
whether there was any bias in terms of the quality of
studies included.
Data synthesis
Given the likelihood that included studies would examine
the relationship of multiple different putative biomarkers
with multiple different clinical measures of disease seve-
rity, we were aware that any data synthesis would be quali-
tative in nature.
Results
As shown in Figure 1, the electronic search identified
4080 records. After removing duplicates, 2435 unique
records identified by the electronic search were screened,
in addition to a further 66 records identified whilst per-
forming the hand search or on reviewing reference lists of
relevant review articles and included articles. The full-text
articles of 409 records were then assessed for eligibility,
and of those 226 articles were excluded. Finally data were
extracted from a total of 183 articles.
Hand searching
Hand searching to validate the electronic search strategy
revealed a sensitivity of 71.4% (95% CI 51.1-86.0) and a
specificity of 97.1% (95% CI 96.5-97.7).
Characteristics of included articles
The majority of included articles (n=156, 85%) had a
cross-sectional study design. The remaining 27 articleshad a longitudinal design, but only 20 (11%) of these
attempted to examine for relevant longitudinal relation-
ships between a change in a biomarker and a change in
a clinical measure of disease severity. The other seven
(4%) simply detailed cross-sectional analyses, and results
from these have been included with data from cross-
sectional studies.
The UK Parkinson’s Disease Society (UKPDS) Brain
Bank Criteria [9] was most commonly used to make the
diagnosis of PD (Table 2), although a large proportion of
studies simply used the presence of the cardinal clinical
features of PD. Over half of included articles did not de-
scribe the setting of their study, but the majority of those
who did were based in outpatient departments. Similarly,
a third of studies failed to mention whether inclusion
and exclusion criteria were applied. Of those providing
this information over half applied moderately to severely
restrictive inclusion/exclusion criteria. No significant dif-
ferences in study characteristics were noted between
longitudinal and cross-sectional studies.
All of the included studies used an impairment or dis-
ability scale as the clinical measure of disease progression
used to test for an association with a biomarker. None of
the studies used duration of survival, or measures of qua-
lity of life or handicap as a clinical outcome measure.
Characteristics of study participants
As illustrated in Table 3 the median number of study
participants was low at 32 (interquartile range (IQR) 21
to 53). With regards to representativeness of all those
with PD, those included were fairly young, with a mean
age of 63.5 (standard deviation (SD) 5.6) years of age,
particularly considering that the median duration of
disease at study entry was 5.7 (IQR 3.6 to 7.4) years. In
keeping with this fairly long duration of disease most
included patients were already on treatment at baseline,
and had moderate disease severity scores. Cognition was
only mildly impaired, with many studies excluding pa-
tients with dementia.
Patients included in longitudinal studies had a signifi-
cantly shorter disease duration at baseline (P = 0.005)
and were less likely to be on treatment (P = 0.005) than
those included in cross-sectional studies. In keeping with
this, they also had milder disease at baseline, with sig-
nificantly better UPDRS (II) scores and lower Hoehn
and Yahr stages than those in cross-sectional studies.
Quality criteria
The median total score produced by applying the adapted
quality questionnaire to each of the included studies was
4.0 (IQR 3.0 to 4.0) out of a possible six. There was no
significant difference in the total score achieved by longi-
tudinal (median 4.0 (IQR 3.0 to 4.8)) and cross-sectional
(median 4.0 (IQR 3.0 to 4.0) studies (P = 0.125, Mann
Studies included 
in final analysis
(n = 183)
Full-text articles excluded
(n = 226)
No diagnostic criteria stated (119)
No relevant associations described (34)
Foreign language paper (15)
Only associations with individual 
symptoms or parts of cognition (12)
Post-mortem study (11)
Other (35)
Full-text articles 
assessed for eligibility 
(n = 409)
Records excluded on 
screening 
(n = 2014)Records screened
(n = 2501)
Records after duplicates removed 
(n = 2501)
Additional records identified by 
reviewing reference lists (58) 
and hand searching (8) 
(n = 66)
Records identified by database 
searches: MEDLINE (1950 - Aug 
2010), Embase (1980 - Aug 2010)
(n = 4080)
Unable to locate full text 
of article 
(n = 4)
Records excluded as 
review article 
(n = 74)
Figure 1 Flow diagram outlying the selection procedure to identify 183 articles included in the systematic review of biomarkers for
disease progression in PD. Note that of the 58 articles identified by reviewing reference lists, 41 were excluded, one article could not be
located and 16 were included in the final qualitative synthesis. All eight articles identified by hand searching (all cross-sectional) were included in
the final qualitative synthesis.
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(questions one, four and five) had almost no discrimina-
ting value, being rated in the affirmative for almost every
included article.Types of biomarkers investigated
A broad spectrum of different biomarker modalities
were investigated in the studies included in this system-
atic review (Table 4). Brain single-photon emission tom-
ography (SPECT) and positron emission tomography
(PET) imaging, along with tests of blood and its constit-
uents, and cerebrospinal fluid formed the majority of
biomarkers investigated. Longitudinal studies mainly
examined the potential of PET and SPECT imaging as a
biomarker of disease progression.Longitudinal studies
In the 20 studies which examined for relevant longitu-
dinal associations, the mean number of longitudinal time
points (including the baseline time point) was 2.2 (SD0.4), with a median time period from baseline to the
final time point of 2.0 (IQR 1.1 to 3.5) years.
Additional file 3 details the biomarkers examined in the
20 longitudinal studies and their relationship with clinical
measures of disease severity. Nine undertook brain
SPECT imaging, eight brain PET imaging, one brain MRI,
one electrophysiological studies, and one acoustical ana-
lysis following a four sentence reading task. Among other
parameters the imaging studies examined the relationship
between clinical measures (total UPDRS, UPDRS (II),
UPDRS (III), Hoehn and Yahr stage [19], MMSE and
CAMCOG) and uptake in the caudate, putamen and stri-
atum. A variety of different PET and SPECT ligands were
used. These included ligands which provide a measure
of cerebral glucose metabolism ([18F]-2-fluoro-2-deoxy-
glucose [FDG]) and cerebral blood flow (N-isopropyl-P
[123I]-iodoamphetamine; [99mTc]-hexamethylpropylene
amine oxidase [HMPAO]), although the majority were
ligands used to measure pre-synaptic dopaminergic
function, either relating to fluorodopamine synthesis
and storage ([18F]6-fluoro-L-3,4-dihydroxyphenylalanine)
Table 2 Study characteristics of the 183 included articles
All studies
(n=183)
Longitudinal studies
(n=20)
Cross-sectional studies
(n=163)
P value
n % n % n %
Diagnostic criteria
UKPDS Brain Bank criteria 89 48.6 11 55.0 78 47.9 0.472
Clinical features 53 29.0 8 40.0 45 27.6
Calne criteria 16 8.7 1 5.0 15 9.2
National Institute of Neurological Disorders
and Stroke criteria
11 6.0 0 0.0 11 6.7
Weiner and Lang criteria 9 4.9 0 0.0 9 5.5
Other 5 2.7 0 0.0 5 3.1
Setting
Outpatient 86 47.0 10 50.0 76 46.6 0.859
Inpatient 2 1.1 0 0.0 2 1.2
Not detailed 95 51.9 10 50.0 85 52.2
Inclusion/Exclusion criteria
None 1 0.5 0 0.0 1 0.6 0.213
Mildly restrictive 22 12.0 1 5.0 21 12.9
Moderately restrictive 65 35.5 11 55.0 54 33.1
Severely restrictive 35 19.1 1 5.0 34 20.9
Not detailed 60 32.8 7 35.0 53 32.5
The P value column relates to association between study type (longitudinal and cross-sectional studies) and 1) Diagnostic criteria, 2) Setting, 3) Inclusion/exclusion
criteria using Pearson’s chi squared tests.
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([18F]-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoro-
propyl)-N-tropane [[18F]FP-CIT]; [123I]-2β-carbometho-
xy-3β-(4-iodophenyl)-N-(3-fluoropropyl)-N-tropane
[[123I]FP-CIT]; [123I]-2β-carbomethoxy-3β-(4-iodophenyl
tropane) [[123I]β-CIT]; 2β-carbomethoxy-3β-(4-[18F])-
fluorophenyl) tropane [[18F]CFT]). Thismarked heterogeneityTable 3 Baseline characteristics of study participants in the 1
All studies
(n=183)
Lo
Baseline demographics
Median number of patients 32 (21 to 53) 31
Mean age (years) 63.5 (5.6) 63.7
Mean percentage male 58.7 (13.9) 67.3
Median disease duration (years) 5.7 (3.6 to 7.4) 3.2
Median percentage treated 76.8 (51.2 to 88.8) 40.6
Baseline disease severity
Median total UPDRS 33.3 (29.4 to 40.6) 31.8
Median UPDRS (II) 14.7 (11.6 to 16.3) 9.1
Median UPDRS (III) 21.0 (16.6 to 26.3) 22.4
Median Hoehn & Yahr 2.5 (2.0 to 2.8) 1.8
Median MMSE 25.8 (23.0 to 28.1) 25.5
Means are presented with standard deviations, and medians with interquartile rang
longitudinal and cross-sectional studies using the Mann–Whitney test.in the studies unfortunately made quantitative synthesis of the
extracted data impossible.
It is clear from the data presented in Additional file 3
that there is no evidence to support the use of acoustic
analysis or electrophysiological tests as biomarkers for
disease progression in PD. The majority of the imaging
studies found no relationship between imaging parameters83 included articles
ngitudinal studies
(n=20)
Cross-sectional studies
(n=163)
P value
(16 to 36) 34 (22 to 55) 0.058
(6.7) 63.4 (5.5) 0.771
(15.6) 57.7 (13.3) 0.002
(1.7 to 5.9) 5.9 (4.1 to 7.6) 0.005
(0.0 to 71.1) 78.5 (56.7 to 90.2) 0.005
(30.1 to 38.7) 33.3 (29.4 to 40.6) 0.790
(Insufficient data for IQR) 14.8 (11.9 to 16.6) 0.023
(16.3 to 28.5) 20.9 (16.8 to 25.8) 0.864
(1.6 to 2.0) 2.5 (2.1 to 2.9) <0.001
(22.3 to 28.3) 25.8 (23.0 to 28.1) 1.000
es (IQR). The P value column relates to comparisons made between
Table 4 Types of putative biomarkers for disease progression investigated in the 183 included articles
All studies (n=183) Longitudinal studies (n=20) Cross-sectional studies (n=163)
Biomarker modality Number of studies examining
biomarker
% Number of studies examining
biomarker
% Number of studies examining
biomarker
%
Serum/plasma/blood 51 27.9 0 0.0 51 31.3
Brain SPECT 41 22.4 9 45.0 32 19.6
Brain PET 31 16.9 8 40.0 23 14.1
CSF 29 15.8 0 0.0 29 17.8
Brain MRI 15 8.2 1 5.0 14 8.6
Cardiac 123I-MIBG
scintigraphy
9 4.9 0 0.0 9 5.5
Electrophysiology 9 4.9 1 5.0 8 4.9
Ultrasound 7 3.8 0 0.0 7 4.3
Urine 5 2.7 0 0.0 5 3.1
Brain MRS 2 1.1 0 0.0 2 1.2
Other 3 1.6 1 5.0 2 1.2
19 cross-sectional studies examined for a relationship between two different biomarker modalities and a clinical measure of disease progression. (SPECT, single-
photon emission computed tomography; PET, positron emission tomography; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging;
123I-MIBG, 123I-metaiodobenzylguanidine; MRS, magnetic resonance spectroscopy).
Table 5 Comparison of the number of included
longitudinal studies investigating a given biomarker
modality with the number reporting a significant
association between the biomarker modality and a
clinical measure of disease progression
Biomarker
modality
Number of studies
investigating
biomarker modality
Number of studies
reporting a significant
association between
biomarker modality and
a clinical measure of
disease progression
FDOPA brain PET 5 0
DAT brain PET or
SPECT
8 3
FDG brain PET 2 2
SPECT to investigate
cerebral blood flow
3 2
MRI brain 1 0
Electrophysiological
tests
1 0
Other 1 0
PET and SPECT brain imaging studies which used ligands to examine
dopamine active transporter function are grouped together. SPECT studies
which use ligands to investigate cerebral blood flow are also grouped
together. (SPECT, single-photon emission computed tomography; PET, positron
emission tomography; MRI, magnetic resonance imaging; FDOPA,
[18F]6-fluoro-L-3,4-dihydroxyphenylalanine; FDG, [18F]-2-fluoro-2-deoxyglucose;
DAT, dopamine active transporter).
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Table 5. Those which did report a significant relationship
were single studies, examining specific brain regions, with
results which have not been replicated by another group.
In addition they involved small numbers of participants.
No studies reported an economic analysis of using the
biomarker in question, and nor did any report on the
acceptability of the test to individual patients. Whilst
eight (40%) longitudinal studies did not detail the treat-
ment status of patients at baseline, three studies [20-22]
did look at the effect of drug therapy on the biomarker
under examination.
In several longitudinal imaging studies it was impo-
ssible to tell from the text whether the values derived
from specific brain regions which were used to draw
associations with clinical measures, were mean values
(values from left and right hemispheric structures
summed and divided by two) or total values (values from
left and right hemispheric structures simply added to-
gether). This issue was however far more prolific when
examining data from cross-sectional studies.
Cross-sectional studies
Additional file 4 demonstrates the vast array of putative
biomarkers which have been examined in cross-sectional
studies, and the large number of clinical measures used
to try to draw associations with them. Putative blood
and CSF biomarkers examined include structural pro-
teins, neurotransmitters, free-radicals and markers of
oxidative stress, amino acids and their metabolites, cate-
cholamines, metals and their transfer proteins, vitamins
and their carrier proteins, and cytokines. This hetero-
geneity made quantitative synthesis of the extracted dataimpossible. Looking at the data however, no single bio-
marker investigated stands out amongst the others as a
good candidate for further investigation in a longitudinal
study.
Similar to the longitudinal studies, in many cross-
sectional SPECT and PET studies it was impossible to
determine whether the uptake values used to draw
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values for structures present in both hemispheres.
Unfortunately none of the 163 studies treated as cross-
sectional in this review included an analysis of the accep-
tability of the test in question to the patients. Regarding
the influence of anti-parkinsonian drug therapy on the
biomarker examined, 25 cross-sectional studies did exa-
mine this issue to some extent.
Statistics
Correlation analysis, a basic statistical method which can
be used to examine for a relationship between two vari-
ables, was solely used in 75% (15/20) of longitudinal
studies. Only one study [23] used a relevant regression
analysis. This study was not designed as a biomarker
study, but rather as a drug study to compare the rate of
dopamine neuron degeneration after initial treatment
with either pramipexole or levodopa in early PD using
[123I]β-CIT SPECT. The association between change
from baseline in UPDRS score (dependent variable) and
the percentage change from baseline in [123I]β-CIT up-
take (independent variable) was examined using a mul-
tiple regression model that adjusted for initial treatment
(pramipexole, levodopa) and baseline UPDRS score. The
paper states that the analysis was performed separately
for each time point (22, 34 and 46 months) at which pa-
tients had a follow-up scan. However, despite stating
that this occurred, details of the outcome are not given
in the paper; correlations are simply described with a
correlation coefficient (r value) and the level of signifi-
cance (P value). There was no analysis that used data
from all time points in a single statistical analysis, rather
than analysing the change from baseline to each time
point separately.
Similarly the majority of cross-sectional studies simply
used basic correlation analysis rather than more complex
statistical techniques.
Overall the standard of reporting results from statistical
analyses in the included longitudinal and cross-sectional
studies was poor. 83.1% of longitudinal correlations
(examined by Pearson’s or Spearman’s correlation ana-
lyses), and 58.8% of cross-sectional correlations, described
neither a correlation coefficient nor the direction of asso-
ciation. Furthermore in 81.4% of longitudinal correlations
and 61.0% of cross-sectional correlations a P value was
not given. No study included in this review detailed confi-
dence intervals for a given correlation coefficient.
Discussion
We found insufficient evidence to support the use of any
biomarker to measure motor or non-motor disease pro-
gression in PD clinical trials. It has also proven difficult
to determine which of the current candidate biomarkers
merits selection over the others for further investigation.Whilst some of the putative imaging biomarkers exam-
ined longitudinally (e.g. FDG PET) may look promising
given the evidence presented in Table 5, unfortunately
this is not really the case. In the case of FDG PET two
papers examined this biomarker and both found a sig-
nificant association between the change in a FDG PET
measure and a change in the motor UPDRS. However,
both studies only included 15 patients, which is a rela-
tively small number of participants from which to draw
conclusions. They also both examined different FDG ex-
pression patterns and only found that some (four out of
six) of these patterns showed a significant association with
a change in the motor UPDRS. Given the differences be-
tween the studies it was not possible to meta-analyse their
results in a meaningful way. As with other imaging moda-
lities we, therefore, felt there was insufficient evidence to
single out FDG PET for further investigation.
It is possible that the lack of a current biomarker is be-
cause no suitable biomarker exists or, at least, no single
biomarker given the complexity of the disease. However,
at present, it probably also reflects the very poor quality
of studies which have investigated biomarkers for disease
progression in PD. In order to improve future studies, we
therefore suggest a provisional ‘roadmap’ for conducting
biomarker studies in this area, detailed in Figure 2. In
addition, we recommend new quality criteria supported
by evidence from this review, detailed in Table 6, by which
future studies may be judged.
The starting point for any biomarker study must be a
valid reason for selecting the specific biomarker for inves-
tigation, based on the pathophysiology of PD. In many
studies included in this systematic review the reasons for
selecting putative biomarkers for investigation were rather
tenuous. Just because a substance can be measured does
not mean an attempt should be made to find an associ-
ation between that substance and clinical measures of dis-
ease severity. This approach, as demonstrated by this
systematic review, is likely to be fruitless. Moreover, the
identification of a biomarker was not the primary aim of
many studies included in this review but rather a by-
product of another study. Disease progression biomarker
studies need carefully planned specific designs as high-
lighted by our ‘roadmap’.
Secondly, the reliability of a putative biomarker must
be established by demonstrating the reproducibility of its
measurement in a single centre by different personnel,
and between different centres. This can be a particular
issue for CSF proteins and for imaging biomarkers, where
a change in a small area of the brain is often measured.
Before proceeding it must be confirmed that such specific
imaging biomarkers can be measured with a reliable
degree of consistency across different centres, which may
have different imaging equipment and software, otherwise
the putative biomarker is likely to be of limited use.
Ensure there is a valid reason
for selecting the putative 
biomarker for investigation 
based on the pathophysiology of 
Parkinson’s disease
Demonstrate the reliability of 
the biomarker by showing 
reproducibility of measurement 
in one centre by different 
personnel, and between centres
Examine the effect of 
confounding factors (e.g. age, 
sex, smoking status or
symptomatic treatment) on the 
biomarker
Undertake a power calculation
to determine an appropriate 
sample size for the biomarker 
study
Perform biomarker study
Longitudinal and prospective
Biomarker and clinical measures 
recorded at several time points over 
several years
Appropriate statistical modelling used 
(e.g. linear mixed models)
Detailed and complete reporting of 
results
Examine the validity and 
reliability of the criterion
(e.g. clinical rating scale)
Figure 2 Flow diagram outlying a provisional ‘roadmap’ for conducting a study to determine whether a given biomarker is a suitable
surrogate for a clinical measure of disease progression.
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tors on the biomarker (e.g. age, gender, smoking status or
being on symptomatic treatment for PD) should be under-
taken. An understanding of the influence of confounding
factors on the biomarker will aid sample size calculations,
and allow a rigorous analysis of the final study results by
adjusting for these factors. This hopefully should avoid
erroneous results which reflect a confounding factor
rather than a true relationship between a biomarker and a
clinical measure of disease progression.
Ideally to be a useful biomarker for neuroprotective
clinical trials the biomarker should not be influenced by
symptomatic treatment. This would simplify trial design
meaning patients on and off treatment could be recruited
and would mean those going on to treatment would nothave to be censored. However, where symptomatic treat-
ment has a limited effect on a given biomarker then
knowledge of this may still allow inclusion of patients on
treatment in clinical trials with appropriate adjustment of
their results. Nonetheless the measurement of biomarkers
which will be significantly influenced by symptomatic PD
therapy (e.g. plasma dopamine or FDOPA PET uptake) is
unlikely to be helpful, as the biomarker will have very li-
mited clinical utility.
In parallel to this pre-study ‘work-up’ of the biomarker,
the validity, reliability, and responsiveness, including to
clinical change, of the selected criterion (e.g. clinical rating
scale) against which a biomarker will be examined, must
be explored. Much work has been undertaken in assessing
the validity and reliability of psychometric instruments
Table 6 New quality criteria to assess studies examining surrogate biomarkers for disease progression
Question Yes No
(1) Was the primary aim of the study to validate a biomarker for disease progression?
(2) Did the study detail a scientifically valid reason for choosing the given biomarker for investigation?
(3) Has the reproducibility of measuring the biomarker in the same centre by different trained personnel, and between centres, been
evaluated?
(4) Has an assessment of the effect of likely confounding factors (e.g. age, gender, smoking status, and being on symptomatic PD
treatment) on the measurement of the biomarker been made?
(5) Has an assessment of the validity and reliability of the criterion (e.g. clinical rating scale) used been made?
(6a) Was a power calculation undertaken to determine the required number of participants?
(6b) If a power calculation was undertaken, was the number of participants included appropriate?
(7) Was the study longitudinal?
(8) Was the study prospective?
(9) Was there a sufficient period of follow-up?
(10) Were the biomarker and clinical measures of disease severity measured on ≥3 occasions?
(11) Was measurement of the biomarker blind to participant characteristics?
(12) Did ≥ 75% of participants entering the study complete the full follow-up period?
(13) Were cases unselected/unbiased (no exclusion criteria)?
(14) Were associations between the biomarker and clinical measures of disease severity examined for using appropriate statistical
modelling (e.g. linear mixed modelling) with adjustment for confounding factors, rather than simply correlation analysis?
(15) Were results of statistical analyses reported in sufficient detail to allow the inclusion of the study results in a meta-analysis?
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ximising the scientific rigor of the selected criterion is
central to improving the chance of coming to the correct
conclusion about the efficacy of a biomarker for disease
progression, and will have implications for biomarker
study sample size calculations.
Following completion of all these preliminary steps it
should then be possible to undertake a power calculation
to determine an appropriate sample size for the bio-
marker study. Unfortunately no studies included in this
review performed a power calculation, and the small num-
ber of participants (median 32 (IQR 21 to 53)) in these
studies is of concern. As studies get smaller it becomes
increasingly likely that potentially significant associations
will not be detected, and limits the number of variables
that can be included in multivariate analyses without
significantly increasing the risk of spurious findings. In a
heterogeneous disease such as PD, small sample sizes also
mean the cohort is unlikely to be representative of all
patients with PD.
Whilst cross-sectional studies formed the majority
of articles included in this systematic review, a cross-
sectional design is not suitable to examine for a relation-
ship between a change in a clinical measure and the
change in a biomarker over time within individual pa-
tients with PD. The longitudinal studies included in this
review had a median follow-up duration of 2.0 (IQR 1.1
to 3.5) years. There is currently no evidence to suggest
what the minimum duration of a surrogate outcome bio-
marker study should be. Undoubtedly it needs to be longenough for a clinically significant change in the criterion,
used to draw associations with the putative biomarker,
to be observed. However, if a short-term change in a
biomarker is to be associated with a long-term change in
a clinical outcome measure then clearly a longer period
of follow-up is required. In the included longitudinal
studies the biomarker and clinical measures were gener-
ally only measured twice (mean 2.2 (SD 0.4) time
points), which is clearly insufficient to allow the differen-
tiation of a linear from a non-linear association. Future
biomarker studies must be longitudinal, and measure
the biomarker and clinical measures at several time
points (at least three) over a sufficient follow-up period,
which is more likely to be measured in years than
months, as only this design will provide sufficient evi-
dence of a biomarkers potential validity.
Parkinson’s disease is a clinically heterogeneous dis-
order, with patients varying significantly in terms of age
of onset, presentation and progression of motor and
non-motor features. Ideally, biomarker studies should be
large enough and use broad enough inclusion criteria to
capture this heterogeneity and identify the utility of the
biomarker in different subgroups of patients. The use of
moderately to severely restrictive inclusion and exclusion
criteria in most of the studies included in this review has
influenced the characteristics of the study participants.
The mean age of participants in included studies was
only 63.5 (SD 5.6) years. Given that the median duration
of disease at study entry was 5.7 (IQR 3.6 to 7.4) years,
these patients have fairly early onset disease. As PD is
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patients may, therefore, not be representative of the ma-
jority of patients with PD. Future studies should justify
their inclusion and exclusion criteria, and try to minim-
ise the latter to avoid limiting the generalisability of their
results or highlight their limited generalisability.
The general reporting of results in the included studies
was poor, making data extraction and interpretation diffi-
cult. This was particularly true of many imaging studies,
where there was often ambiguity as to whether stated
values were mean values or total values for structures
represented in both hemispheres. Similarly there was often
a failure to report important methodological features, such
as the study setting, or whether inclusion and exclusion
criteria were applied.
The reporting of the statistical analyses was also inad-
equate. In both correlation and regression analyses, hy-
pothesis testing can be undertaken to determine whether
a relationship exists in the population as a whole, and con-
fidence intervals calculated to indicate the strength of that
relationship. Whilst significance testing was undertaken in
most included studies, they failed to report confidence
intervals, thereby limiting the ease of interpretation of
analyses. Many studies also omitted to report precise sig-
nificance values, instead simply giving results descriptive
in the text. If due to pressure of space the actual results of
statistical analyses cannot be fully included in a journal
article then data should be provided as an additional on-
line resource. Disappointingly several studies even failed
to detail what statistical techniques they used. Without
clear reporting of the study methodology, results, and the
outcome of statistical analyses, investigators devalue their
study and risk it being excluded from future systemic re-
views or meta-analyses.
The statistical techniques applied in the included studies
were in many cases inappropriate, and more often than
not too simplistic. Unfortunately it appeared that many of
the studies included in this review had been conducted
without input from an experienced statistician. Whilst a
detailed review of the appropriate statistical techniques to
use in disease progression biomarker studies is beyond the
scope of this review, we wish to make a few key points.
The majority of included cross-sectional studies used
correlation analysis to examine for a relationship between
clinical outcome measures and a given biomarker. How-
ever, correlation is a limited technique to use for this
purpose as it only indicates the strength and direction of
a relationship between two variables [26]. Furthermore
correlation does not allow more complex assessment of
the influence of possible confounders, and does not allow
the value of one variable to be predicted when the other is
known.
Several included studies measured a large number of va-
riables and then calculated multiple individual correlationcoefficients and significance values. This sequential testing
of multiple variables makes it more likely that a significant
correlation will be found simply by chance. Multivariate
analysis is the appropriate technique to use when the rela-
tionship between a single dependent variable and several
explanatory variables is examined at the same time, to
avoid the pitfalls of multiple testing. It also has the ad-
vantage of allowing the inclusion of factors which may
affect the relationship between the variables of interest,
and adjusts for these potential confounders. Therefore,
whilst correlation analysis can be viewed as a basic statis-
tical technique which can in certain circumstances be used
to generate hypotheses, higher levels of statistical analysis
should be used to test hypotheses [27].
Use of correlation analysis in longitudinal studies, where
repeated measurements are performed, is inappropriate as
this takes no account of the possible covariance between
measurements recorded in the same individual. However
the use of regression is limited to situations where vari-
ables are measured twice in the same individual. In these
cases regression can be used either by including baseline
measurements as a covariant in the model, or by con-
verting the pairs of measurements recorded in each indi-
vidual into the actual change or percentage change from
baseline, before using these calculated values in the re-
gression model.
Where variables are measured three or more times in
individuals in longitudinal studies, it is possible to under-
take separate analyses to compare variables at baseline
and each subsequent time point individually. However,
this again introduces repeated testing, increasing the like-
lihood of finding a significant association by chance. It
also takes no account of missing data, common in longitu-
dinal studies due to deaths, loss to follow-up or with-
drawal from the study. It is therefore not an approach we
would recommend.
A potential solution to these problems is the use higher
levels of statistical modelling, for example linear mixed
models which can be used to test for linear relationships
[28]. In the analysis of repeated measurements from longi-
tudinal studies, these types of models take into account
patients who drop-out early when estimates for later time
points are made. However, the models also ensure that
those with incomplete data do not influence the results as
greatly as those with complete data. Using these models, a
time effect on the repeated measure, independent from dis-
ease progression, is allowed for. In addition as disease pro-
gression may differ across time points these types of model
can allow for this by introducing a ‘disease progression-by
-time interaction’. The non-independence of the repeated
measures can be accounted for by simply assuming there is
a constant correlation for all pairs of measurements in the
same individual or by, for example, varying this correlation
as measurements become more widely separated by time.
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biomarker studies incorporate a range of analyses, rather
than simply correlation, in order to explore the validity
of more advanced statistical methods. The use of appro-
priate statistical techniques should reduce the chance of
type I and type II errors, and thereby allow sensible con-
clusions to be drawn about the efficacy of biomarkers for
disease progression. Such analyses should be conducted
by experienced statisticians, who therefore, need to be in-
volved in the planning and conduct of future studies.
We attempted to group blood and CSF biomarkers into
categories with shared characteristics (e.g. structural pro-
teins, free radicals and markers of oxidative damage, anti-
oxidants, pro-inflammatory cytokines, metals, amino acids,
and vitamins) to see if this would allow any sensible
sub-grouping of the results. However, the biomarkers did
not easily fit into a simple categorical structure and hence
we abandoned this approach.
It could be argued that the failure of included longitu-
dinal studies to detect associations between the change
in clinical measures of disease progression and the
change in a given biomarker reflects a lack of sensitivity
to change in the clinical markers of disease progression
used, rather than a failure of the biomarker to change
with disease progression. However, in the majority of in-
cluded longitudinal studies there was a clear change in
the clinical measures used between time points, making
this hypothesis unlikely.
One potential criticism of our systematic review is that
we included studies whose primary aim was not to de-
velop a biomarker for disease progression in PD. We did
so to ensure that our review was as inclusive as possible
and did not miss potential biomarkers. It does, however,
raise the question of the appropriateness of studies with an
alternative primary aim (for example, drug development) of
undertaking these additional, usually cross-sectional, ana-
lyses to produce information regarding such associations.
As we have highlighted the development of biomarkers for
disease progression in PD requires studies with a primary
objective of biomarker validation, exemplified by a careful
study design. Such studies could be run alongside other
studies (e.g. long-term prognostic studies or clinical trials)
but only if appropriately planned and funded. Conflicts of
interest and issues around the subsequent ownership and
availability of biomarkers in the public domain may arise if
biomarkers are developed in clinical trials funded by
pharmaceutical companies and these issues need to be con-
sidered beforehand.
Some of the lessons of this systematic review, in par-
ticular the necessity for longitudinal studies measuring
putative biomarkers and clinical measures several times
over several years, have begun to be realised by some re-
searchers and have started to be put into practice. In PD
the Parkinson’s Progression Markers Initiative (PPMI)[29] and the Parkinson’s Disease Biomarkers Program
(PDBP) [30] both aim to measure various putative CSF,
blood, and imaging biomarkers over several years. Their
work, like that of the longitudinal Alzheimer’s Disease
Neuroimaging Initiative (ADNI) [31] in Alzheimer’s dis-
ease, should mark a major shift in the quality of studies
of biomarkers for disease progression, and hopefully lead
to advances in this important field.
Conclusions
This extensive systematic review has highlighted the meth-
odological, statistical and reporting flaws of studies exam-
ining biomarkers for disease progression in Parkinson’s
disease. It is clear that continuing to publish small cross-
sectional studies in this area is unlikely to yield significant
results. We have suggested methodological guidelines
which we hope will provide a better chance of making pro-
gress in this area, and would value feedback on them.
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